败血症诊断市场－全球产业规模、份额、趋势、机会和预测，按技术、产品、诊断方法、病原体、地区和竞争细分，2020 年至 2030 年

2024 年全球败血症诊断市场价值为 6.1225 亿美元，预计到 2030 年将达到 9.5418 亿美元，预测期内复合年增长率为 7.68%。败血症是一种危及生命的严重疾病，由对感染的免疫反应不平衡引起，导致全身性发炎和潜在的器官衰竭。及时诊断和治疗对于提高患者存活率和预防併发症至关重要。全球败血症发病率的不断上升，加上医疗专业人员和公众意识的不断提高，推动了对快速且准确的诊断解决方案的需求。随着分子技术、免疫测定和自动血液培养系统的进步，败血症诊断已经有了显着的发展。这些技术可以更早地检测和识别病原体，从而实现及时的治疗介入。老龄人口对感染的敏感度不断增加，以及住院人数的增加，进一步促进了市场的成长。随着医疗保健系统优先考虑早期败血症管理，在创新和持续研发的努力下，对高效诊断工具的需求持续成长。

关键市场驱动因素

败血症诊断技术的进展

主要市场挑战

通用竞争

主要市场趋势

生物标记发现

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球败血症诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按技术（分子诊断、微生物学、免疫测定和其他技术）
  • 副产品（仪器、分析试剂和其他产品）
  • 依诊断方法（常规诊断和自动诊断）
  • 依病原体（细菌性败血症、真菌性败血症和其他病原体）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美败血症诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲败血症诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太败血症诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲败血症诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲败血症诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购

第 13 章：全球败血症诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代治疗类型的威胁

第 15 章：竞争格局

• Abbott Laboratories Inc.
• DiaSorin SpA
• Becton, Dickinson and Company
• BioMerieux Inc.
• F. Hoffmann-La Roche AG
• Danaher Corporation
• Thermo Fisher Scientific Inc
• Siemens Healthineers AG
• Seegene, Inc.
• Roche Diagnostics Corporation

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Sepsis Diagnostics Market was valued at USD 612.25 Million in 2024 and is projected to reach USD 954.18 Million by 2030, growing at a CAGR of 7.68% during the forecast period. Sepsis is a critical, life-threatening condition resulting from an imbalanced immune response to infection, leading to systemic inflammation and potential organ failure. Prompt diagnosis and treatment are essential to improve patient survival and prevent complications. The growing incidence of sepsis globally, coupled with heightened awareness among healthcare professionals and the public, is driving the demand for rapid and accurate diagnostic solutions. Sepsis diagnostics have evolved significantly with advancements in molecular techniques, immunoassays, and automated blood culture systems. These technologies allow earlier detection and pathogen identification, enabling timely therapeutic interventions. The increasing susceptibility of the aging population to infections, along with rising hospital admissions, further contributes to market growth. As healthcare systems prioritize early sepsis management, the demand for efficient diagnostic tools continues to grow, bolstered by innovation and ongoing R&D efforts.

Key Market Drivers

Advancements in Sepsis Diagnostic Technologies

Technological innovation has played a central role in transforming sepsis diagnosis, significantly enhancing accuracy and speed. Key advancements include the use of polymerase chain reaction (PCR) for the rapid identification of microbial DNA or RNA, and next-generation sequencing (NGS), which offers comprehensive pathogen detection in a single test. Automated blood culture systems and antibiotic-neutralizing blood culture bottles have improved diagnostic reliability in septic patients undergoing antimicrobial treatment. Additionally, the development of immunoassays for biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) enables clinicians to assess infection severity and guide treatment decisions. Lateral flow assays now allow point-of-care testing for quicker triage. Host gene expression analysis and emerging microRNA biomarkers also show promise in distinguishing sepsis from other inflammatory conditions. These innovations are enabling faster clinical decision-making, reducing mortality, and expanding the sepsis diagnostics landscape.

Key Market Challenges

Generic Competition

The emergence of generic alternatives in the diagnostic sector presents a significant challenge for established players in the sepsis diagnostics market. Once patent protections expire, generic manufacturers often introduce cost-effective diagnostic solutions that create pricing pressure and reduce profit margins for original manufacturers. This market dynamic forces branded companies to adopt more competitive pricing strategies, potentially affecting their revenue streams. Moreover, the widespread availability of generics can reduce the market share of innovative firms and discourage future investments in R&D, slowing the pace of diagnostic innovation. Ensuring the quality and accuracy of generic diagnostics remains a concern, prompting the need for strict regulatory oversight. Despite offering affordability, generics can disrupt established business models, compelling original manufacturers to differentiate through technological enhancements or value-added services.

Key Market Trends

Biomarker Discovery

Biomarker discovery is rapidly shaping the future of sepsis diagnostics, offering improved precision and speed in identifying and managing the condition. Biomarkers provide specific biological indicators that help differentiate sepsis from other inflammatory or infectious conditions. Their use enables more accurate and earlier diagnoses, which are crucial for timely intervention. Biomarkers such as procalcitonin, CRP, and cytokine profiles are increasingly used to assess infection severity and monitor treatment responses. Additionally, the development of multiplex assays that simultaneously evaluate multiple biomarkers is enhancing diagnostic accuracy. The rise of microRNA profiling and host gene expression analysis is further expanding the biomarker toolkit, allowing for personalized diagnostic approaches. These innovations support the shift toward precision medicine in sepsis care, facilitating targeted and effective treatment strategies. The growing pipeline of biomarker-based tests is expected to fuel market growth by providing clinicians with reliable tools to improve patient outcomes.

Key Market Players

• Abbott Laboratories
• DiaSorin SpA
• Becton, Dickinson, and Company
• BioMerieux Inc.
• F. Hoffmann-La Roche AG
• Danaher Corporation
• Thermo Fisher Scientific Inc
• Siemens Healthineers AG
• Seegene, Inc.
• Roche Diagnostics Corporation

Report Scope:

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology:

• Molecular Diagnostics
• Microbiology
• Immunoassay
• Other Technologies

Sepsis Diagnostics Market, By Product:

• Instruments
• Assays and Reagents
• Other Products

Sepsis Diagnostics Market, By Diagnostic Method:

• Conventional Diagnostics
• Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Other Pathogens

Sepsis Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sepsis Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies)
  • 5.2.2. By Product (Instruments, Assays and Reagents, and Other Products)
  • 5.2.3. By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics)
  • 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Sepsis Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Diagnostic Method
  • 6.2.4. By Pathogen
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Sepsis Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Diagnostic Method
      • 6.3.1.2.4. By Pathogen
  • 6.3.2. Canada Sepsis Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Diagnostic Method
      • 6.3.2.2.4. By Pathogen
  • 6.3.3. Mexico Sepsis Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Diagnostic Method
      • 6.3.3.2.4. By Pathogen

7. Europe Sepsis Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Diagnostic Method
  • 7.2.4. By Pathogen
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Sepsis Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Diagnostic Method
      • 7.3.1.2.4. By Pathogen
  • 7.3.2. United Kingdom Sepsis Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Diagnostic Method
      • 7.3.2.2.4. By Pathogen
  • 7.3.3. Italy Sepsis Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Diagnostic Method
      • 7.3.3.2.4. By Pathogen
  • 7.3.4. France Sepsis Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Diagnostic Method
      • 7.3.4.2.4. By Pathogen
  • 7.3.5. Spain Sepsis Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Diagnostic Method
      • 7.3.5.2.4. By Pathogen

8. Asia-Pacific Sepsis Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Diagnostic Method
  • 8.2.4. By Pathogen
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Sepsis Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Diagnostic Method
      • 8.3.1.2.4. By Pathogen
  • 8.3.2. India Sepsis Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Diagnostic Method
      • 8.3.2.2.4. By Pathogen
  • 8.3.3. Japan Sepsis Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Diagnostic Method
      • 8.3.3.2.4. By Pathogen
  • 8.3.4. South Korea Sepsis Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Diagnostic Method
      • 8.3.4.2.4. By Pathogen
  • 8.3.5. Australia Sepsis Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Diagnostic Method
      • 8.3.5.2.4. By Pathogen

9. South America Sepsis Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Diagnostic Method
  • 9.2.4. By Pathogen
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Sepsis Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Diagnostic Method
      • 9.3.1.2.4. By Pathogen
  • 9.3.2. Argentina Sepsis Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Diagnostic Method
      • 9.3.2.2.4. By Pathogen
  • 9.3.3. Colombia Sepsis Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Diagnostic Method
      • 9.3.3.2.4. By Pathogen

10. Middle East and Africa Sepsis Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Diagnostic Method
  • 10.2.4. By Pathogen
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Sepsis Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Diagnostic Method
      • 10.3.1.2.4. By Pathogen
  • 10.3.2. Saudi Arabia Sepsis Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Diagnostic Method
      • 10.3.2.2.4. By Pathogen
  • 10.3.3. UAE Sepsis Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Diagnostic Method
      • 10.3.3.2.4. By Pathogen

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Sepsis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. DiaSorin SpA
• 15.3. Becton, Dickinson and Company
• 15.4. BioMerieux Inc.
• 15.5. F. Hoffmann-La Roche AG
• 15.6. Danaher Corporation
• 15.7. Thermo Fisher Scientific Inc
• 15.8. Siemens Healthineers AG
• 15.9. Seegene, Inc.
• 15.10. Roche Diagnostics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer